Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1379-1385

  De Bruijn, Menno T ^a   Raats, Daniëlle A E ^a   Tol, Jolien ^b   Hinrichs, John ^a   Teerenstra, Steven ^b   Punt, Cornelis J A ^b   Borel Rinkes, Inne H M ^a   Kranenburg, Onno ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil; CAIRO2; Capecitabine; Clinical; Colorectal; KRAS; Oxaliplatin; p53; Sequence analysis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; K RAS PROTEIN; OXALIPLATIN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DNA, NEOPLASM; FLUOROURACIL; HUMANS; MUTATION; ORGANOPLATINUM COMPOUNDS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79956068762     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
3. Giacchetti S, Perpoint B, Zidani R, Le BN, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le RA, Walter S, Adam R, Misset JL and Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147, 2000. (Pubitemid 30036347)
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
5. Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Goldberg RM: Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26: 5721-5727, 2008.
6. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, Aranes MJ, Lesser M, Schwartz EL and Augenlicht LH: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63: 8791-8812, 2003. (Pubitemid 38064059)
7. Cardoso J, Boer J, Morreau H and Fodde R: Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 1775: 103-137, 2007. (Pubitemid 44881195)
8. Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD and Biasco G: Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 99: 1729-1734, 2008.
9. Del RM, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P and Ychou M: Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 25: 773-780, 2007. (Pubitemid 350002876)
10. Koopman M and Punt CJ: Chemotherapy, which drugs and when. Eur J Cancer 45(Suppl 1): 50-56, 2009.
11. Klampfer L, Swaby LA, Huang J, Sasazuki T, Shirasawa S and Augenlicht L: Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis. Oncogene 24: 3932-3941, 2005. (Pubitemid 40896405)
12. Smakman N, van den Wollenberg DJ, Elias SG, Sasazuki T, Shirasawa S, Hoeben RC, Borel RI and Kranenburg O: KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 66: 5403-5408, 2006.
13. de Bruijn MT, Raats DA, Hoogwater FJ, van Houdt WJ, Cameron K, Medema JP, Borel RI and Kranenburg O: Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Br J Cancer 102: 1254-1264, 2010.
14. Loriot Y, Mordant P, Deutsch E, Olaussen KA and Soria JC: Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 6: 528-534, 2009.
15. Benhattar J, Cerottini JP, Saraga E, Metthez G and Givel JC: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69: 190-192, 1996. (Pubitemid 26233297)
16. Bouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, Saraga E, Pampallona S, Bosman FT and Givel JC: p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36: 1008-1015, 2000. (Pubitemid 30316426)
17. Munro AJ, Lain S and Lane DP: P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 92: 434-444, 2005. (Pubitemid 40395523)
18. Russo A, Migliavacca M, Bazan V, Maturi N, Morello V, Dardanoni G, Modica G, Bazan P, Albanese I, La FM and Tomasino RM: Prognostic significance of proliferative activity, DNA-ploidy, p53 and Ki-ras point mutations in colorectal liver metastases. Cell Prolif 31: 139-153, 1998. (Pubitemid 28529022)
19. Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung CS, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, O'Donoghue DP, Agnese V, Cascio S, Di FG, Chieco-Bianchi L, Bertorelle R, Belluco C, Giaretti W, Castagnola P, Ricevuto E, Ficorella C, Bosari S, Arizzi CD, Miyaki M, Onda M, Kampman E, Diergaarde B, Royds J, Lome RA, Diep CB, Meling GI, Ostrowski J, Trzeciak L, Guzinska-Ustymowicz K, Zalewski B, Capella GM, Moreno V, Peinado MA, Lonnroth C, Lundholm K, Sun XF, Jansson A, Bouzourene H, Hsieh LL, Tang R, Smith DR, len-Mersh TG, Khan ZA, Shorthouse AJ, Silverman ML, Kato S and Ishioka C: Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 17: 842-847, 2006.
20. Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Verlind E, Hermans J, Poppema S, Buys CH and Plukker JT: Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum 44: 358-363, 2001. (Pubitemid 32226324)
21. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O and Punt CJ: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572, 2009.
22. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629, 2007. (Pubitemid 46744292)
23. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P, Cromer A, Brugge JS, Sansom OJ, Norman JC and Vousden KH: Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341, 2009.
24. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K and Urosevic N: Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85: 692-696, 2001.
25. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La FM, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N and Russo A: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446, 2002.
26. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW and Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274, 2006. (Pubitemid 44571966)